DOI QR코드

DOI QR Code

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease

  • Hwang, Hyunjung (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Shin, Ji Young (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Kyu Ree (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Shin, Jae Ouk (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Song, Kyoung-hwan (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Joonhyung (Department of Internal Medicine, Incheon Christian Hospital) ;
  • Park, Jeong Woong (Division of Pulmonary and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center)
  • Received : 2015.04.29
  • Accepted : 2015.06.26
  • Published : 2015.10.30

Abstract

Background: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced by starting roflumilast at half the dose, and then increasing a few weeks later to $500{\mu}g$ daily. Methods: We retrospectively investigated 85 patients with COPD who had taken either $500{\mu}g$ roflumilast, or a starting dose of $250{\mu}g$ and then increased to $500{\mu}g$. We analyzed all adverse events and assessed differences between patients who continued taking the drug after dose escalation and those who had stopped. Results: Adverse events were reported by 22 of the 85 patients (25.9%). The most common adverse event was diarrhea (10.6%). Of the 52 patients who had increased from a starting dose of $250{\mu}g$ roflumilast to $500{\mu}g$, 43 (82.7%) successfully maintained the $500{\mu}g$ roflumilast dose. No difference in factors likely to affect the risk of adverse effects, was detected between the dose-escalated and the discontinued groups. Of the 26 patients who started with the $500{\mu}g$ roflumilast regimen, seven (26.9%) discontinued because of adverse effects. There was no statistically significant difference in discontinuation rate between the dose-escalated and the control groups (p=0.22). Conclusion: Escalating the roflumilast dose may reduce treatment-related adverse effects and improve tolerance to the full dose. This study suggests that the dose-escalated regimen reduced the rate of discontinuation. However, longer-term and larger-scale studies are needed to support the full benefit of a dose escalation strategy.

Keywords

References

  1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21. https://doi.org/10.1016/S0140-6736(04)16900-6
  2. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71. https://doi.org/10.1016/S0140-6736(05)67100-0
  3. Lahu G, Facius A. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther 2013; 51:832-6. https://doi.org/10.5414/CP201906
  4. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5. https://doi.org/10.1006/pupt.1999.0181
  5. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
  6. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. https://doi.org/10.1164/rccm.201204-0596PP
  7. Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012;91:134-42. https://doi.org/10.1038/clpt.2011.266
  8. Beghe B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 2013; 188:271-8. https://doi.org/10.1164/rccm.201301-0021PP
  9. Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 2011; (204):415-46.
  10. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67. https://doi.org/10.1111/j.1476-5381.2011.01218.x
  11. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94. https://doi.org/10.1016/S0140-6736(09)61255-1

Cited by

  1. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis vol.15, pp.8, 2016, https://doi.org/10.1080/14740338.2016.1199683
  2. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease vol.194, pp.5, 2015, https://doi.org/10.1164/rccm.201606-1179pp
  3. Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study vol.81, pp.4, 2015, https://doi.org/10.4046/trd.2018.0015
  4. Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology vol.24, pp.10, 2015, https://doi.org/10.1111/resp.13633